Esophageal adenocarcinoma · 5 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
ECF/5-FU and RT Variant #01 | — | R 6 300 | 63d | — | — | ~2 | ~R 8 743 indirect | — |
FULV and RT Variant #04 | — | R 2 014 | 14d | — | 36.0 mo | 1 | R 2 014 PFS proxy | 1 |
Cisplatin and Irinotecan (IC) Variant #01 | — | R 1 795 | 21d | ~3.8 mo | ~13.9 mo | ~4 | ~R 7 181 PFS proxy · indirect | 2 |
Cisplatin and Paclitaxel (TP) Variant #02 | — | R 1 315 | 21d | ~5.6 mo | ~11.1 mo | ~7 | ~R 9 204 PFS proxy · indirect | 8 |
Observation Partial | — | — | — | ~3.4 mo | ~36.1 mo | — | — | 18 |
5 of 5 regimens shown